Megaburn Capsule contains Orlistat 120 mg, a potent lipase inhibitor indicated for the management of obesity. Orlistat acts locally in the gastrointestinal tract by selectively inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By preventing the breakdown and subsequent absorption of approximately 30% of dietary fat, Megaburn Capsule facilitates weight reduction in conjunction with a reduced-calorie diet. This medication is intended for use in adults with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or greater who present with other risk factors such as hypertension, type 2 diabetes, or dyslipidemia. Clinical studies have demonstrated that Orlistat, when combined with lifestyle modifications including diet and exercise, significantly improves weight loss outcomes and contributes to the improvement of obesity-related comorbidities. Megaburn Capsule should be taken with each main meal containing fat, and adherence to a nutritionally balanced, reduced-calorie diet is essential to minimize gastrointestinal adverse effects such as oily stools and flatulence. Use is contraindicated in patients with chronic malabsorption syndrome or cholestasis. Regular monitoring of liver function and fat-soluble vitamin levels is recommended during prolonged therapy.